Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis. Issue 3 (2nd March 2023)

• Record Type: Journal Article
• Authors: He, Wenjuan; Zhang, Yuqian; Huang, Guangliang; Tian, Yunfei; Sun, Qian; Liu, Xiuju
• Is Part Of: LUTS. Volume 15:Issue 3(2023)
• Page Start: 80
• Page End: 88
• Publication Date: 2023-03-02
• Subjects: mirabegron -- network meta‐analysis -- overactive bladder -- randomized controlled trials -- vibegron; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12475
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract: Objectives: The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder. Methods: A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively. Results: A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo. Conclusions: Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.